Clinuvel is currently carries high volatility, the positive uptrend is appealing for short-term swing trades. Clinuvel is currently near its previous resistance. From a technical analysis, I don’t believe it is currently in the “good buy” territory. However, if Clinuvel continues to make “higher highs and higher lows,” that break the resistance, Clinuvel might offer a substantial profit. Click the title of the post to read more.
Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO®
Heron Therapeutics Receives Complete Response Letter For HTX-011 For The Management Of Postoperative Pain Heron received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) on April 30, 2019.¹ A CRL is sent to drug manufacturers to indicate that the review cycle for an application is complete and that the application … Continue reading Update to Heron Therapeutics, Inc. (Nasdaq: HRTX)
Agios Pharmaceuticals, Inc. is a company I see potential value in. From a technical analysis standpoint, it appears a reversal was confirmed in 2019 and has trended positively. It appears to have met a resistance around $66 and currently found a support near $56. If the support is confirmed, Agios may continue following their positive trend. I have not taken a position; however, this company is currently on my watch list. This company currently has two approved products, TIBSOVO® (ivosidenib) and IDHIFA® (enasidenib), and three other products in clinical development.
Heron Therapeutics, Inc. is a company I see potential value in. I have not taken a position; however, this company is currently on my watch list. This company currently has two approved products, SUSTOL® (granisetron) and CINVANTI® (aprepitant). HTX-011 (bupivacaine and meloxicam) is their investigational product that has a Prescription Drug User Fee Act (PDUFA) date of 30 April 2019.